Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 761: Verapamil is associated with all of the following except?

A. Constipation
B. Bradycardia
C. Hyperglycemia (Correct Answer)
D. Increased PR interval

Explanation: **Explanation:** Verapamil is a non-dihydropyridine Calcium Channel Blocker (CCB) with significant effects on both cardiac muscle and smooth muscle. **Why Hyperglycemia is the Correct Answer:** Verapamil does **not** typically cause hyperglycemia. In fact, calcium channel blockers are generally considered metabolically neutral. Interestingly, some studies suggest that Verapamil may actually improve beta-cell function and lower blood glucose levels in diabetic patients by inhibiting TXNIP (thioredoxin-interacting protein). Therefore, hyperglycemia is not a recognized side effect of Verapamil. **Analysis of Incorrect Options:** * **Constipation (Option A):** This is the **most common side effect** of Verapamil. It occurs due to the blockade of L-type calcium channels in the gastrointestinal smooth muscle, leading to decreased intestinal motility. * **Bradycardia (Option B):** Verapamil has potent negative chronotropic (decreased heart rate) and negative inotropic effects. It acts on the SA node to slow the heart rate, making bradycardia a frequent side effect. * **Increased PR Interval (Option D):** Verapamil significantly slows conduction through the AV node (negative dromotropic effect). On an ECG, this manifests as a prolongation of the PR interval. It is used therapeutically to control ventricular rate in atrial fibrillation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Verapamil is the drug of choice for **Prophylaxis of Paroxysmal Supraventricular Tachycardia (PSVT)** and Cluster Headaches. * **Contraindication:** Never co-administer Verapamil with **Beta-blockers** intravenously, as it can lead to severe bradycardia, AV block, or asystole due to additive cardiosuppressant effects. * **Gingival Hyperplasia:** Like phenytoin and cyclosporine, CCBs (especially Nifedipine and Verapamil) can cause gum enlargement.

Question 762: Which of the following beta-blockers does NOT possess membrane stabilizing properties?

A. Acebutolol
B. Betaxolol
C. Carvedilol
D. Bevantolol (Correct Answer)

Explanation: Membrane Stabilizing Activity (MSA), also known as a "quinidine-like effect" or local anesthetic activity, refers to the ability of certain beta-blockers to inhibit the initiation and propagation of action potentials by blocking voltage-gated sodium channels. This property is typically seen at high plasma concentrations and is clinically relevant in cases of drug overdose. 1. **Why Bevantolol is the Correct Answer:** **Bevantolol** is a cardioselective (β1) antagonist that also possesses some α1-blocking activity. Crucially, it is categorized among the beta-blockers that **lack** membrane stabilizing properties [1]. In the context of this question, it is the outlier compared to the other listed drugs. 2. **Analysis of Incorrect Options:** * **Acebutolol:** A cardioselective beta-blocker that possesses significant MSA and also exhibits Intrinsic Sympathomimetic Activity (ISA). * **Betaxolol:** A highly selective β1-blocker that is known to have mild to moderate membrane stabilizing activity. * **Carvedilol:** A non-selective beta and alpha-1 blocker used in heart failure; it possesses potent MSA along with antioxidant properties. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for MSA (+):** "**P**roperly **M**aintain **A**ll **L**evels" (**P**ropranolol, **M**etoprolol, **A**cebutolol, **L**abetalol). Propranolol has the highest MSA. * **Clinical Significance:** Drugs with MSA are generally avoided in patients with certain cardiac conduction defects, but this property makes them useful in treating specific arrhythmias. * **Water-soluble Beta-blockers (e.g., Atenolol, Sotalol):** These generally lack MSA and have a lower risk of CNS side effects as they do not cross the blood-brain barrier.

Question 763: Which of the following is a glycoprotein IIb/IIIa receptor antagonist?

A. Clopidogrel
B. Abciximab (Correct Answer)
C. Tranexamic acid
D. Ticlopidine

Explanation: The **Glycoprotein (GP) IIb/IIIa receptor** is the final common pathway for platelet aggregation. When activated, these receptors bind to fibrinogen, forming cross-links between adjacent platelets to create a platelet plug [5]. **Why Abciximab is Correct:** **Abciximab** is a chimeric monoclonal antibody that binds irreversibly to the GP IIb/IIIa receptor, preventing fibrinogen binding and subsequent platelet aggregation [1]. Other drugs in this class include **Eptifibatide** (a cyclic peptide) and **Tirofiban** (a non-peptide small molecule) [1], [2]. These are potent antiplatelet agents typically used in Acute Coronary Syndrome (ACS) and during Percutaneous Coronary Intervention (PCI) [1]. **Analysis of Incorrect Options:** * **Clopidogrel & Ticlopidine:** These belong to the **P2Y12 receptor antagonists** (Thienopyridines). They work by inhibiting the ADP-induced pathway of platelet activation, which is upstream of the GP IIb/IIIa receptor [4]. * **Tranexamic acid:** This is an **Antifibrinolytic** agent. It works by inhibiting the conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots [3]. It is used to control bleeding, not as an antiplatelet. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** GP IIb/IIIa inhibitors are the most potent antiplatelets because they block the "final common pathway." * **Abciximab Side Effect:** It can cause significant **thrombocytopenia**; platelet counts should be monitored [1]. * **Route:** All GP IIb/IIIa inhibitors are administered **intravenously** [2]. * **Antidote:** For Abciximab, the effect is long-lasting; if life-threatening bleeding occurs, a **platelet transfusion** is required [1].

Question 764: Which of the following drugs is used for the management of pulmonary hypertension?

A. Carboprost
B. Misoprostol
C. Indomethacin
D. Bosentan (Correct Answer)

Explanation: **Explanation:** **Bosentan** is the correct answer because it is a **competitive dual endothelin receptor antagonist (ERA)**, blocking both $ET_A$ and $ET_B$ receptors. Endothelin-1 is a potent endogenous vasoconstrictor and smooth muscle mitogen that is significantly elevated in patients with Pulmonary Arterial Hypertension (PAH). By blocking these receptors, Bosentan decreases pulmonary vascular resistance and prevents vascular remodeling. **Analysis of Incorrect Options:** * **Carboprost (PGF2α analog):** Primarily used for postpartum hemorrhage (PPH) and mid-trimester abortion. It causes bronchoconstriction and vasoconstriction, making it unsuitable for pulmonary hypertension. * **Misoprostol (PGE1 analog):** Used for medical abortion (in combination with Mifepristone) and prevention of NSAID-induced peptic ulcers. It does not have a primary role in managing PAH. * **Indomethacin (NSAID):** A non-selective COX inhibitor used to promote the **closure of a Patent Ductus Arteriosus (PDA)** in neonates. It is not used to treat pulmonary hypertension. **High-Yield Clinical Pearls for NEET-PG:** * **Bosentan Side Effects:** The most significant side effect is **hepatotoxicity** (requires monthly LFT monitoring) and it is highly **teratogenic** (Category X). * **Other PAH Drugs:** * **PDE-5 Inhibitors:** Sildenafil, Tadalafil. * **Prostacyclin Analogs:** Epoprostenol (drug of choice for severe PAH), Treprostinil, Iloprost. * **Soluble Guanylate Cyclase Stimulator:** Riociguat. * **Macitentan** is a newer ERA with better tissue penetration and less hepatotoxicity compared to Bosentan.

Question 765: Trimetazidine is used for which of the following conditions?

A. Hypertension
B. Angina (Correct Answer)
C. Congestive Heart Failure (CHF)
D. Arrhythmia

Explanation: **Explanation:** **Trimetazidine** is a unique anti-anginal agent classified as a **pFOX (partial Fatty Acid Oxidation) inhibitor**. 1. **Why Angina is Correct:** Trimetazidine acts as a **metabolic modulator**. It inhibits the enzyme **3-ketoacyl-CoA thiolase (3-KAT)**, which shifts the myocardial metabolism from fatty acid oxidation to **glucose oxidation**. Since glucose oxidation requires less oxygen to produce the same amount of ATP compared to fatty acids, the drug improves myocardial energy efficiency. This protects the heart from ischemic injury without affecting heart rate or blood pressure, making it an effective add-on therapy for **Stable Angina Pectoris**. 2. **Why Other Options are Incorrect:** * **Hypertension:** Trimetazidine has no vasodilator properties and does not affect systemic vascular resistance; hence, it is not used for hypertension. * **CHF:** While metabolic support is beneficial, Trimetazidine is not a primary treatment for CHF. Standard therapy involves ACE inhibitors, Beta-blockers, and Diuretics. * **Arrhythmia:** It does not block ion channels (Sodium, Potassium, or Calcium) and thus lacks anti-arrhythmic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits 3-KAT enzyme → Shifts metabolism to glucose → Preserves ATP levels during ischemia. * **Hemodynamics:** It is a "pure" metabolic agent; it does **not** alter heart rate, blood pressure, or double product. * **Side Effects:** Can cause **Parkinsonian symptoms** (tremors, rigidity) and gait disturbances; it is contraindicated in patients with Parkinson’s disease. * **Similar Drug:** **Ranolazine** also acts on myocardial metabolism but primarily works by inhibiting the **late sodium current ($I_{Na}$)**.

Question 766: Which is the shortest acting beta-blocker?

A. Propranolol
B. Esmolol (Correct Answer)
C. Timolol
D. Atenolol

Explanation: **Explanation:** **Esmolol** is the shortest-acting beta-blocker due to its unique chemical structure. It is an ester, which allows it to be rapidly hydrolyzed by **red blood cell esterases** (not plasma cholinesterase). This results in an ultra-short half-life of approximately **9 minutes**. Because of this rapid metabolism, it must be administered via intravenous infusion and is easily titratable; if side effects occur, they resolve quickly once the infusion is stopped. **Analysis of Incorrect Options:** * **Propranolol:** A prototype non-selective beta-blocker with a half-life of 3–4 hours. It is lipid-soluble and undergoes significant first-pass metabolism. * **Timolol:** A non-selective beta-blocker primarily used topically for glaucoma. Its systemic half-life is approximately 4 hours. * **Atenolol:** A cardioselective (Beta-1) blocker that is water-soluble (hydrophilic) and excreted unchanged by the kidneys. It has a half-life of 6–9 hours, allowing for once-daily dosing. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Esmolol is the drug of choice for intraoperative tachycardia, hypertensive emergencies (especially aortic dissection), and supraventricular arrhythmias where rapid control is needed. * **Selectivity:** It is a **cardioselective (Beta-1)** antagonist. * **Metabolism:** Remember it is metabolized by **RBC esterases**. This makes it safe to use in patients with liver or kidney dysfunction. * **Longest acting beta-blocker:** Nadolol (half-life of 14–24 hours).

Question 767: Which of the following drugs can increase the calcium sensitivity of myocytes?

A. Omapatrilat
B. Levosimendan (Correct Answer)
C. Milrinone
D. Sacubitril

Explanation: ### Explanation **Correct Option: B. Levosimendan** Levosimendan belongs to a class of drugs known as **Calcium Sensitizers**. It exerts its positive inotropic effect by binding to **Troponin C** in a calcium-dependent manner. This stabilizes the calcium-induced conformational change in the troponin complex, increasing the sensitivity of myofilaments to existing calcium without increasing the actual intracellular calcium concentration. Levosimendan has been approved for use in acute failure in Europe and has shown noninferiority against dobutamine [1]. This is clinically significant because it enhances myocardial contractility without increasing myocardial oxygen demand or causing arrhythmias associated with calcium overload. Additionally, it acts as a vasodilator by opening ATP-sensitive potassium channels. **Incorrect Options:** * **A. Omapatrilat:** This is a Vasopeptidase inhibitor that inhibits both Neprilysin and ACE. It was developed for hypertension and heart failure but is not a calcium sensitizer. * **C. Milrinone:** This is a **PDE-3 inhibitor**. It increases cAMP levels, which leads to an *increase* in intracellular calcium levels in myocytes [2]. While it is an inodilator, its mechanism is distinct from calcium sensitization. * **D. Sacubitril:** This is a **Neprilysin inhibitor** used in combination with Valsartan (ARNI) for heart failure [3]. It prevents the degradation of natriuretic peptides but has no direct effect on myocyte calcium sensitivity. **High-Yield Facts for NEET-PG:** * **Levosimendan Triple Action:** 1. Inotropy (Troponin C binding), 2. Vasodilation ($K_{ATP}$ channel opening), 3. Cardioprotection (mitochondrial $K_{ATP}$ channels). * **Advantage:** Unlike Dobutamine or Milrinone, Levosimendan does not increase the risk of calcium-induced arrhythmias. * **Pimobendan:** Another calcium sensitizer often mentioned in this category. * **Clinical Use:** Primarily used in acute decompensated heart failure.

Question 768: What is the mechanism of action of Gemfibrozil?

A. HMG CoA reductase inhibitor
B. Activates lipoprotein lipase (Correct Answer)
C. Inhibitor of lipolysis
D. Bile acid sequestrant

Explanation: **Explanation:** **Gemfibrozil** belongs to the **Fibrate** class of hypolipidemic drugs. Its primary mechanism of action involves the activation of **Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α)**, a nuclear receptor. Activation of PPAR-α leads to the increased transcription of genes that code for **Lipoprotein Lipase (LPL)**. LPL is the key enzyme responsible for the hydrolysis of triglycerides in chylomicrons and VLDL, thereby significantly lowering plasma triglyceride levels. **Analysis of Options:** * **A. HMG CoA reductase inhibitor:** This is the mechanism of **Statins** (e.g., Atorvastatin), which primarily lower LDL cholesterol by inhibiting the rate-limiting step of cholesterol synthesis. * **C. Inhibitor of lipolysis:** This refers to **Niacin (Vitamin B3)**, which inhibits hormone-sensitive lipase in adipose tissue, reducing the flow of free fatty acids to the liver. * **D. Bile acid sequestrant:** These are resins like **Cholestyramine**, which bind bile acids in the intestine, preventing their enterohepatic circulation and forcing the liver to use cholesterol to synthesize new bile acids. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fibrates are the first-line treatment for **severe hypertriglyceridemia** (TG >500 mg/dL) to prevent acute pancreatitis. * **Side Effects:** The most significant risk is **myopathy/rhabdomyolysis**, which is greatly increased when fibrates (especially Gemfibrozil) are co-administered with Statins. * **Contraindications:** Avoid in patients with hepatic or severe renal dysfunction and gallbladder disease (as fibrates increase the lithogenicity of bile, leading to gallstones).

Question 769: Which anti-androgen is used in heart failure?

A. Carvedilol
B. Sampatrilat
C. Spironolactone (Correct Answer)
D. Abiraterone

Explanation: **Explanation:** **Spironolactone** is the correct answer because it is a **Mineralocorticoid Receptor Antagonist (MRA)**. While primarily used in heart failure to block the deleterious effects of aldosterone on the myocardium (preventing cardiac fibrosis and remodeling), it is chemically a steroid derivative with significant **anti-androgenic properties**. It acts as a competitive antagonist at the androgen receptor and inhibits 17α-hydroxylase, leading to side effects like gynecomastia and decreased libido, which are high-yield clinical markers for this drug. **Analysis of Options:** * **A. Carvedilol:** A non-selective beta-blocker with alpha-1 blocking activity. While it is a cornerstone in heart failure management (reducing mortality), it has no anti-androgenic activity. * **B. Sampatrilat:** A dual inhibitor of Angiotensin-Converting Enzyme (ACE) and Neutral Endopeptidase (NEP). It was studied for heart failure and hypertension but is not classified as an anti-androgen. * **D. Abiraterone:** A potent anti-androgen (CYP17 inhibitor) used in metastatic castration-resistant prostate cancer. It is **not** used to treat heart failure; in fact, it can cause fluid retention and hypertension due to mineralocorticoid excess. **High-Yield Clinical Pearls for NEET-PG:** * **RALES Trial:** Demonstrated that Spironolactone reduces mortality in NYHA Class III and IV heart failure. * **Eplerenone:** A more selective MRA with fewer anti-androgenic side effects (less gynecomastia) compared to Spironolactone. * **Potassium Sparing:** Both are potassium-sparing diuretics; the most critical side effect to monitor is **hyperkalemia**, especially when combined with ACE inhibitors or ARBs.

Question 770: What is the typical time taken for digitalization in cardiac therapy?

A. 36 hours
B. 12 hours
C. 5 days (Correct Answer)
D. 10 days

Explanation: **Explanation:** The correct answer is **5 days** because of the pharmacokinetic principle of **Steady State Concentration**. 1. **Why 5 days is correct:** Digoxin has a long elimination half-life ($t_{1/2}$) of approximately **36 to 40 hours** in patients with normal renal function. In clinical pharmacology, it takes roughly **4 to 5 half-lives** for a drug to reach a steady-state concentration in the plasma when given at a constant maintenance dose. * Calculation: $1.5 \text{ days (half-life)} \times 4 \text{ to } 5 = 6 \text{ to } 7.5 \text{ days}$. * In the context of standard medical examinations like NEET-PG, "5 days" is the recognized clinical benchmark for achieving digitalization (therapeutic levels) without using a loading dose. 2. **Why other options are incorrect:** * **36 hours (Option A):** This represents only *one* half-life of Digoxin. At this point, only 50% of the steady-state concentration is achieved, which is insufficient for full digitalization. * **12 hours (Option B):** This is far too short for a drug with such a long half-life. This timeframe might only reflect the distribution phase, not the elimination kinetics. * **10 days (Option D):** While steady state would certainly be reached by day 10, it is achieved much earlier (by day 5–7). This option is less precise than the standard pharmacological rule. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Na⁺/K⁺-ATPase pump, leading to increased intracellular Ca²⁺ (positive inotropy) and increased vagal tone (negative chronotropy). * **Loading Dose:** If rapid digitalization is required (e.g., in acute atrial fibrillation), a "loading dose" or "priming dose" is given to bypass the 5-day wait. * **Toxicity:** Digoxin has a **narrow therapeutic index** (0.5–2 ng/mL). Toxicity is precipitated by **Hypokalemia** (as K⁺ competes with Digoxin for the Na⁺/K⁺-ATPase binding site). * **Antidote:** Digibind (Digoxin-specific antibody fragments).

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free